Industry News
to-BBB receives ind approval for novel brain cancer drug, 2B3-101
Aug 21, 2013
to-BBB, the brain drug delivery company, is pleased to announce the successful completion of its 2B3-101 Phase I part of its clinical trial in brain cancer patients, safely reaching clinically effective dosages... Read More
Total tumor dimensions predict survival in advanced non-small cell lung cancer
Aug 21, 2013
For the two-thirds of lung cancer patients with locally advanced or metastatic disease, tumor size is not used currently to predict overall survival times. A new study, however, led by UT Southwestern Medical Center researchers has shown that even in advanced stages total tumor size can have a major impact on survival... Read More
In subarachnoid hemorrhage, complications associated with continuous cerebrospinal fluid drainage
Aug 21, 2013
Researchers at Duke University conducted a randomized clinical trial in patients with subarachnoid hemorrhage (SAH). In this study, the researchers compared two approaches to intracranial pressure management - continuous and intermittent drainage of cerebrospinal fluid (CSF) - and outcomes associated with those methods, focusing specifically on the incidence of cerebral vasospasm... Read More
Glioblastoma survival improved following FDA approval of bevacizumab
Aug 21, 2013
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer... Read More
BI-RADS 3 breast lesions found to have low cancer rate in multicenter trial
Aug 21, 2013
Based on data from a multi-site imaging trial involving more than 2,600 women, researchers say breast lesions categorized as 'probably benign' on supplemental screening ultrasound could be re-evaluated with imaging in 12 months, reducing patient anxiety, follow-up exams and unnecessary biopsies. Results of the study are published online in the journal Radiology... Read More
Glioblastoma response to anti-angiogenesis therapy revealed by new MR analysis technique
Aug 20, 2013
A new way of analyzing data acquired in MR imaging appears to be able to identify whether or not tumors are responding to anti-angiogenesis therapy, information that can help physicians determine the most appropriate treatments and discontinue ones that are ineffective... Read More
Anglia Ruskin experts want introduction of new treatment model for ductal carcinoma in situ (DCIS) patients
Aug 20, 2013
Breast cancer specialists at Anglia Ruskin University are proposing the introduction of a new model to provide safer treatment for patients with ductal carcinoma in situ (DCIS), the most common form of non-invasive breast cancer... Read More
Treatment-resistant lymphomas 'reprogrammed' to respond to cancer drugs
Aug 20, 2013
A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research... Read More
Cancer-fighting immune activity boosted by dialing back Treg cell function in animal model
Aug 20, 2013
By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy - harnessing the body's immune system to attack tumors. To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses... Read More
Long-term side-effects in testicular cancer could be reduced by chemotherapy before radiotherapy
Aug 20, 2013
Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports... Read More
Previous Page Next Page